AR071650A1 - USE OF GLICOSAMINOGLYCAN TO RESTORE GLICOCALIX - Google Patents

USE OF GLICOSAMINOGLYCAN TO RESTORE GLICOCALIX

Info

Publication number
AR071650A1
AR071650A1 ARP090101200A ARP090101200A AR071650A1 AR 071650 A1 AR071650 A1 AR 071650A1 AR P090101200 A ARP090101200 A AR P090101200A AR P090101200 A ARP090101200 A AR P090101200A AR 071650 A1 AR071650 A1 AR 071650A1
Authority
AR
Argentina
Prior art keywords
glycocalix
damage
glycosaminoglycan
restore
glycosaminoglycans
Prior art date
Application number
ARP090101200A
Other languages
Spanish (es)
Inventor
Hans Vink
Erik Sjoerd Gerard Stroes
Original Assignee
Univ Maastricht
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Maastricht filed Critical Univ Maastricht
Publication of AR071650A1 publication Critical patent/AR071650A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invencion esta dirigida al uso de gIicosaminoglicanos para restaurar las funciones del gIicocalix o prevenir el dano del glicocalix. La efectividad de los gIicosaminogIicanos es dirigida a todas las patolog¡as donde el dano del glicocalix o esto funcion puede ser la causa etiologica de muchas patolog¡as tales como: enfermedad vascular, estado septico, s¡ndrome de ateroesclerosis, estados de inflamacion y enfermedades relacionadas con isquemia, deterioro peritoneal, infarto de miocardio, eventos cerebrovascuIares, alteracion de la glicosilacion enzim tica en diabetes, lesion renal, enfermedades intestinales como condiciones de colitis ulcerosa, neumoconiosis que involucra la alteracion de la actividad metabolica del endotelio pulmonar. Reivindicacion 2: El uso, de acuerdo con la reivindicacion 1, caracterizado en que el glicosaminoglicano es sulodexida. Reivindicacion 3: El uso descrito en la reivindicacion 2 en la preparacion de una medicina administrable por v¡a oral, parenteral, intranasal, pulmonar, transdermal topica, rectal, vaginal para restaurar las funciones del glicocalix o prevenir el dano del glicocalix Reivindicacion 5: Una composicion farmaceutica para restaurar o prevenir el dano del glicocalix, la cual comprende una cantidad terapeuticamente efectiva de glicosaminoglicano o una mezcla de m s de un glicosaminoglicano con excipientes farmaceuticamente aceptables.The invention is directed to the use of glycosaminoglycans to restore the functions of glycocalix or prevent damage of glycocalix. The effectiveness of glycosaminoglycans is directed to all pathologies where glycocalix damage or this function may be the etiological cause of many pathologies such as: vascular disease, septic state, atherosclerosis syndrome, inflammation states and diseases related to ischemia, peritoneal deterioration, myocardial infarction, cerebrovascular events, alteration of enzymatic glycosylation in diabetes, renal injury, intestinal diseases such as conditions of ulcerative colitis, pneumoconiosis that involves the alteration of the metabolic activity of the pulmonary endothelium. Claim 2: The use, according to claim 1, characterized in that the glycosaminoglycan is sulodexidant. Claim 3: The use described in claim 2 in the preparation of a medicine administrable by oral, parenteral, intranasal, pulmonary, topical, rectal, vaginal transdermal route to restore glycocalix functions or prevent glycocalix damage Claim 5: A pharmaceutical composition for restoring or preventing glycocalix damage, which comprises a therapeutically effective amount of glycosaminoglycan or a mixture of more than one glycosaminoglycan with pharmaceutically acceptable excipients.

ARP090101200A 2008-04-04 2009-04-03 USE OF GLICOSAMINOGLYCAN TO RESTORE GLICOCALIX AR071650A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08154102 2008-04-04

Publications (1)

Publication Number Publication Date
AR071650A1 true AR071650A1 (en) 2010-07-07

Family

ID=39651254

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090101200A AR071650A1 (en) 2008-04-04 2009-04-03 USE OF GLICOSAMINOGLYCAN TO RESTORE GLICOCALIX

Country Status (3)

Country Link
CN (1) CN101632686A (en)
AR (1) AR071650A1 (en)
WO (1) WO2009121959A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140021725A (en) 2005-12-13 2014-02-20 엑스테라 메디컬 코퍼레이션 Method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from blood
IT1401253B1 (en) * 2010-04-23 2013-07-18 Uni Degli Studi Carlo Bo Urbino USE OF SULODEXIDE FOR THE REDUCTION OF MATRIX METALLOPROTEINASE.
JP2017513636A (en) 2014-04-24 2017-06-01 エクスセラ メディカル コーポレイション Method for removing bacteria from blood using high flow rate
KR20170060062A (en) 2014-09-22 2017-05-31 엑스테라 메디컬 코퍼레이션 Wearable hemoperfusion device
AU2016245994A1 (en) * 2015-04-08 2017-11-30 Microvascular Health Solutions, LLC Synergistic glycocalyx treatment compositions and methods
WO2016164534A1 (en) * 2015-04-09 2016-10-13 Kardiatonos, Inc. Methods and compositions for reversing disruption of the glycocalyx, inflammation, and oxidative damage
CA3022351A1 (en) 2015-04-29 2016-11-03 Kardiatonos, Inc. Methods and compositions for reversing disruption of the glycocalyx, inflammation, and oxidative damage
US11911551B2 (en) 2016-03-02 2024-02-27 Exthera Medical Corporation Method for treating drug intoxication
WO2020231830A1 (en) * 2019-05-16 2020-11-19 Exthera Medical Corporation Method for modulating endothelial glycocalyx structure

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1245907B (en) * 1991-05-17 1994-10-25 Alfa Wassermann Spa USE OF GLYCOSAMINOGLICANS IN THE TREATMENT OF DIABETIC NEPHROPATHY AND DIABETIC NEUROPATHY.
IT1270846B (en) * 1993-05-10 1997-05-13 Alfa Wassermann Spa USE OF SULODEXIDE AND MEDICINAL SPECIALTIES THAT CONTAIN IT IN THE TREATMENT OF DIABETIC NEPHROPATHY.
IT1274351B (en) * 1994-10-06 1997-07-17 Alfa Wassermann Spa USE OF SOME GLYCOSAMINOGLICANS IN PERITONEAL DIALYSIS.
IT1299969B1 (en) * 1998-04-15 2000-04-04 Alfa Wassermann Spa USE OF SULODEXIDE AND MEDICINAL SPECIALTIES THAT CONTAIN IT IN THE TREATMENT OF DIABETIC RETINOPATHY.
US7259152B2 (en) * 2000-06-07 2007-08-21 Alfa Wasserman, Inc. Methods and compositions using sulodexide for the treatment of diabetic nephropathy
WO2006121853A1 (en) * 2005-05-05 2006-11-16 Keryx Biopharmaceuticals, Inc. Combination therapy with sulodexide and a blood pressure reducing agent in the treatment of diabetic nephropathy

Also Published As

Publication number Publication date
CN101632686A (en) 2010-01-27
WO2009121959A1 (en) 2009-10-08

Similar Documents

Publication Publication Date Title
AR071650A1 (en) USE OF GLICOSAMINOGLYCAN TO RESTORE GLICOCALIX
UY32820A (en) DP2 RECEPTOR ANTAGONIST DERMATOLOGICAL COMPOSITIONS
ES2916604T1 (en) Nrf2 Detection Assays and Related Methods and Compositions
AR085662A1 (en) METHODS AND COMPOSITIONS TO TREAT HYPERURICEMIA AND METABOLIC DISORDERS ASSOCIATED WITH HYPERURICEMIA
AR068820A1 (en) PHARMACEUTICAL COMPOSITION UNDERSTANDING THE COMBINATION OF VENOTONIC AGENTS AND VASOPROTECTORS FOR THE TREATMENT OF CHRONIC VENOUS INSUFFICIENCY AND USE
AR077605A1 (en) SUBCUTANEOUS FORMULATION OF ANTIBODY ANTIBODY2
CO7240407A2 (en) Crystal forms of an androgenic receptor modulator
CL2012000872A1 (en) Compounds derived from iminothiadiazine dioxide, inhibitors of aspartyl protease bace-1, salt of the compound, pharmaceutical composition comprising a compound and use of the compounds in the preparation of medicaments for the treatment of diseases related to ß-amyloid ("aß "), such as Alzheimer's.
AR093181A1 (en) FORMULATION WITH CONTENT OF DIGESTIVE ENZYMES UNDER STABLE
CO6150136A2 (en) BENZOIL ADAPALENE AND PEROXIDE COMBINATION TO TREAT ACNE INJURIES
AR090601A1 (en) QUINURENINE-3-MONOOXIGENASA INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF THE SAME USE
PE20130496A1 (en) LUPUS ARTHRITIS TREATMENT USING LAQUINIMOD
CL2012000446A1 (en) Use of a topical vesicular formulation comprising one or more phospholipids and one or more surfactants in a molar ratio of 1: 1 to 25: 1 phospholipids to surfactants, for the treatment of inflammatory dermatous disorders.
WO2009074794A3 (en) Anti-inflammatory compositions and combinations
MX353712B (en) Dimethyl sulfoxide (dmso) and methylsulfonylmethane (msm) formulations to treat osteoarthritis.
ECSP13012538A (en) COMBINATIONS CONTAINING N- (2-ARILAMINO) ARILSULFONAMIDE REPLACED
AR081082A1 (en) ORGANIC COMPOSITIONS TO TREAT DISEASES RELATED TO BETA-ENAC
PE20180026A1 (en) TOPICAL CURATIVE COMPOSITION
CO6280488A2 (en) PHARMACEUTICAL COMBINATION
PE20080673A1 (en) RAPID DISINTEGRATION FREEZE DRIED ORAL FORMULATIONS OF A THROMBIN RECEPTOR ANTAGONIST
BR112012015437A2 (en) substantially anhydrous stable storage topical composition
AR078393A1 (en) INHIBITION OF THE FORMATION OF ADHESIONS IN THE TENDONS
AR066666A1 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMBINATION OF AN NON-STEROID ANTI-INFLAMMATORY AGENT AND AN ANTI-CONVULSIVING AGENT
AR065917A1 (en) PHARMACEUTICAL COMPOSITION IN THE FORM OF A SUBLINGUAL TABLET THAT INCLUDES A NON-STEROID ANTI-INFLAMMATORY AND AN OPIACEAL ANALGESIC FOR PAIN MANAGEMENT
AR083095A1 (en) APREPITANT L-PROLINA AND PHARMACEUTICAL COMPOSITION CO-CRYSTAL

Legal Events

Date Code Title Description
FB Suspension of granting procedure